Kasi, A., Al-Rajabi, R. M. T., Li, H., Carroll, E., Bradbury, S., Broxterman, C., Phadnis, M. A., Baranda, J. C., Sun, W. (2025). A phase II open-label study of sacituzumab govitecan in patients with previously treated locally advanced, recurrent, or metastatic cholangiocarcinoma (SIGNA).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.4_suppl.tps651